⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154433 | 0.81 | MAPT (0.31) | — | |
| SCHEMBL10863938 | 0.73 | NOTUM (0.31) | — | |
| SCHEMBL5154211 | 0.71 | KDM4E (0.37) | — | |
| SCHEMBL5154965 | 0.70 | HSP90AA1 (0.38) | — | |
| Clonidine SCHEMBL5982 | 0.70 | MAPT (0.36) | — | |
| Clonidine SCHEMBL1369983 | 0.70 | MAPT (0.36) | — | |
| Bromide SCHEMBL6726492 | 0.70 | KDM4E (0.36) | — | |
| Clonidine SCHEMBL40751 | 0.69 | ADRA2A (0.36) | — | |
| Clonidine SCHEMBL9838987 | 0.69 | MAPT (0.35) | — | |
| Clonidine SCHEMBL10972183 | 0.69 | ADRA2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | claimed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | claimed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | claimed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | claimed |
| US-8591947-B2 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2013-11-26 | — | — | US | disclosed |
| US-20130108693-A1 | Dual Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2013-05-02 | — | — | US | disclosed |
| US-8329217-B2 | Dual controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2012-12-11 | — | — | US | disclosed |
| US-8241667-B2 | Dual controlled release osmotic device | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2012-08-14 | — | — | US | disclosed |
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20060204578-A1 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2006-09-14 | — | — | US | disclosed |
| US-20060177510-A1 | Dual controlled release osmotic device | ACELLA HOLDINGS, LLC | 2006-08-10 | — | — | US | disclosed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030185882-A1 | Pharmaceutical compositions containing oxybutynin | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2003-10-02 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |